Sign In
Buy PCVX
$51.96
-0.150 (-0.288%)
At Close: Jun 23, 2026
SAN CARLOS, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequ
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
04:05pm, Thursday, 01'st Feb 2024
SAN CARLOS, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequ
Vaxcyte Announces Pricing of $750 Million Public Offering
11:37pm, Tuesday, 30'th Jan 2024
SAN CARLOS, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequ
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:01pm, Tuesday, 30'th Jan 2024
SAN CARLOS, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequ
-- Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Phase 1/2 Study (n=1,015) Expected in Third Quarter of 2024 -- -- VAX-31 is Designed to Provide Coverage for Approximately 95% of I
Vaxcyte Appoints Whitney Jones as Chief People Officer
04:01pm, Tuesday, 16'th Jan 2024
-- Ms. Jones Joins Vaxcyte With Over 20 Years of Experience Leading People and Culture Strategies Across Multiple Industries -- SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nas
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
04:01pm, Thursday, 04'th Jan 2024
-- Company Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Phase 1/2 Study in Adults Following Independent Review of Phase 1 Safety and Tolerability Data; Topline Safety, Tolerability
-- In the Study, VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20 ® (PCV20) at all Doses Studied -- -- All 24 Serotypes of VAX-24 at Conventional 2.2 mcg PCV Dose Met
Vaxcyte Appoints Jacks Lee to Board of Directors
08:30am, Tuesday, 28'th Nov 2023
SAN CARLOS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacter
-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company's Pneumococcal Conjugate Vaccine (PCV) Franchise -- -- Manufacturing Righ
-- VAX-31, a 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, is the Broadest-Spectrum PCV to Enter the Clinic -- -- Topline Safety, Tolerability and Immunogenicity Data Expected in Second Ha
Vaxcyte to Present at Upcoming Investor Conferences
04:05pm, Tuesday, 31'st Oct 2023
SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequ
Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
04:05pm, Tuesday, 19'th Sep 2023
SAN CARLOS, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conseq
Strong Financials And Pipeline Position Vaxcyte For Success
06:34pm, Thursday, 17'th Aug 2023
Vaxcyte, Inc. is a clinical-stage vaccine company developing high-fidelity vaccines for bacterial diseases. The company's Q2 2023 earnings report shows significant growth in cash and investments, indi
5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good
10:32am, Tuesday, 13'th Jun 2023
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND
